Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MAGE-A1-specific T-cell receptor-transduced autologous T cells

A preparation of autologous CD4- and CD8-positive T lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets the human melanoma-associated antigen A1 (MAGE-A1), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A1-specific TCR-transduced autologous T cells bind to tumor cells expressing MAGE-A1, which may halt the growth of and kill MAGE-A1-expressing cancer cells. MAGE-A1 is a tumor-associated antigen (TAA) overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:MAGE-A1-specific T-cell receptor-transduced autologous CD8+ and CD4+ T cells
MAGE-A1-specific TCR-transduced autologous T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search